Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemoradiotherapy is recommended as standard therapy for resectable esophageal
cancer. The recurrence rate after surgery following neoadjuvant chemoradiotherapy is about
35%. Whether achieving pathological complete response after neoadjuvant chemoradiotherapy is
significantly associated with recurrence after surgery. It is reported that immunotherapy
combined with chemotherapy improved survival compared with chemotherapy alone in first line
therapy of advanced esophageal cancer. We hypothesize that the addition of immunotherapy to
neoadjuvant chemoradiotherapy is helpful to improving pathologic complete response and
survival.